Wegovy (Semaglutide 2.4 mg) Clinical & Endocrinology Guide: Bengaluru

Hospital networks, titration science, and clinical guidance for patients across Bengaluru Urban.

1. Pharmacological Profile & STEP-1 Trial Data

Wegovy (Semaglutide 2.4 mg subcutaneous injection) is a selective GLP-1 receptor agonist. In the landmark STEP-1 clinical trial, patients adhering to structured lifestyle modifications achieved an average 14.9% reduction in total body weight over 68 weeks alongside significant improvements in cardiometabolic markers.

2. Tertiary Healthcare & Specialist Centers in Bengaluru

Bengaluru residents can access specialized endocrinologists and comprehensive metabolic evaluation across top hospitals:

  • Manipal Hospital (Old Airport Road) - Department of Endocrinology
  • Apollo Hospitals (Bannerghatta Road) - Centre for Diabetes & Endocrinology
  • Fortis Hospital (Bannerghatta Road / Cunningham Road) - Endocrine Department
  • Aster CMI Hospital (Hebbal) - Metabolic Disorders & Endocrinology

3. Stepwise Titration Protocol

To mitigate gastrointestinal side effects (nausea, reflux, constipation), Wegovy is titrated in monthly steps:

  • Month 1: 0.25 mg weekly
  • Month 2: 0.50 mg weekly
  • Month 3: 1.00 mg weekly
  • Month 4: 1.70 mg weekly
  • Month 5+: 2.40 mg weekly (Full Therapeutic Maintenance Dose)